Crohn's Disease, Ulcerative Colitis
Conditions
Keywords
Crohn's Disease, Ulcerative colitis, Macrophages, Adherent-Invasive Escherichia coli, Proteomic analysis
Brief summary
The M2iSH laboratory showed with two previous clinical trials that Crohn's Disease (CD) macrophages present i) a defect to control Adherent-Invasive Escherichia coli (AIEC) infection related to polymorphisms associated with CD; ii) a CD - specific cytokine secretion profile after an AIEC infection and intestinal inflammation dependent; iii) a modification of the response of CD macrophages at a basal state and after the AIEC infection. These results consolidate the hypothesis of a defect specific to CD macrophages. That's why, the primary purpose of this study is to realize a proteomic analysis of macrophages of CD patients infected or not with AIEC and to compare them to Ulcerative Colitis (UC) patients and healthy volunteers.
Detailed description
The macrophages characterization will be realized at a basal state and in response or not to AIEC. Investigator aimed to 1) better understand the differences between macrophages of CD patients, UC patients and healthy volunteers but also the impact of AIEC infection on these macrophages to provide key informations to detect and characterize the defect of these macrophages; 2) highlight one or several protein in CD macrophages that could represent, in a long term, a potential therapeutic target of CD.
Interventions
OTHERProteomic analysis
Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
Sponsors
Laboratoire M2Ish
University Hospital, Clermont-Ferrand
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* \- Crohn's Disease or ulcerative colitis or healthy volunteers * Age \> 18 years * Patients benefiting from the health insurance plan * Patients who can read and attest to understanding the information note and informed consent
Exclusion criteria
* Pregnant or breastfeeding woman * Under guardianship or curatorship * Refusing the genetic part of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the proteomic profile of macrophages of patients with CD to patients with UC and healthy subjects in the basal state | at day 1 | Compare concentrations of different protein types in the supernatant of macrophages from patients with CD through proteomic approaches, compared with patients with UC or controls. |
Secondary
| Measure | Time frame |
|---|---|
| presence of subgroups of patients with CD based on the proteomic profile of their macrophages. | at day 1 |
| association between these subgroups of patients with CD and biological parameters. | at day 1 |
| associations between the proteomic profiles of macrophages of patients with CD, UC or control subjects and fecal AIEC status | at day 1 |
| Comparison of concentrations of different protein types in the supernatant of macrophages | at day 1 |
| impact of anti-TNF treatment on the proteomic profile (s) observed for macrophages of patients with CD | at day 1 |
| associations between the Proteomic profile (s) of the macrophages derived from monocytes and their AIEC status | at day 1 |
| associations between the Proteomic profile (s) of tissue macrophages and their AIEC status | at day 1 |
| associations between the levels of entry, survival and multiplication of AIEC bacteria | at day 1 |
Countries
France
Outcome results
None listed